MindMed Study Highlights Urgent Need for Suicide Risk Screening in GAD Patients

Mind Medicine ( (MNMD) ) has issued an announcement.

MindMed presented a study at Psych Congress 2025 revealing that nearly 50% of individuals with severe Generalized Anxiety Disorder (GAD) experience suicidal ideation (SI) almost daily. The study, based on the 2022 National Health and Wellness Survey, highlights the strong link between anxiety severity and SI, emphasizing the need for routine screening. The findings underscore the urgent need for improved suicide risk screening and targeted interventions, particularly for those with GAD and comorbid Major Depressive Disorder (MDD). This research could significantly impact public health strategies and MindMed’s positioning in addressing mental health issues.

The most recent analyst rating on (MNMD) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Mind Medicine stock, see the MNMD Stock Forecast page.

Spark’s Take on MNMD Stock

According to Spark, TipRanks’ AI Analyst, MNMD is a Neutral.

Mind Medicine’s stock score is primarily impacted by its weak financial performance, marked by zero revenue and substantial net losses typical of clinical-stage biotech firms. The strong liquidity position is offset by reliance on equity financing. Technical analysis shows moderate positive momentum, but valuation metrics are unattractive with a negative P/E ratio. The lack of earnings call data and corporate events leaves financial performance as the dominant factor in the overall score.

To see Spark’s full report on MNMD stock, click here.

More about Mind Medicine

Mind Medicine (MindMed) Inc. is a late-stage clinical biopharmaceutical company focused on developing novel product candidates to treat brain health disorders.

Average Trading Volume: 1,225,855

Technical Sentiment Signal: Strong Buy

Current Market Cap: $725.9M

For a thorough assessment of MNMD stock, go to TipRanks’ Stock Analysis page.